Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PDE7A | Q13946 | 9/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FPR1 | P21462 | 2/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20551174 | 0.98 | HPGD (0.54) | HPGDPDE7AKCNH2KDM4EALDH1A1 | |
| SCHEMBL20551368 | 0.97 | HPGD (0.48) | HPGDPDE7AKCNH2KDM4EALDH1A1 | |
| SCHEMBL20551652 | 0.93 | HPGD (0.43) | HPGDPDE7AKDM4ECFTRHCAR3 | |
| SCHEMBL1717307 | 0.87 | HPGD (0.48) | HPGDPDE7AKCNH2BTK | |
| SCHEMBL20550960 | 0.86 | CFTR (0.41) | HPGDPDE7AFPR1CFTR | |
| SCHEMBL4508313 | 0.86 | HPGD (0.50) | HPGDPDE7AKCNH2KDM4EALDH1A1 | |
| SCHEMBL31194583 | 0.84 | HPGD (0.44) | HPGDKCNH2BTK | |
| SCHEMBL20551287 | 0.84 | TEAD1 (0.41) | HPGDKCNH2MEN1KMT2A | |
| SCHEMBL4751212 | 0.82 | HPGD (0.42) | HPGDPDE7AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL4519120 | 0.81 | MAPK1 (0.48) | HPGDPDE7AKCNH2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2020-08-06 | — | — | US | disclosed |
| CN-110914263-A | Substituted bicyclic heterocyclic compounds as NADPH oxidase inhibitors | 格兰马克药品股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3619209-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018203298-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-11-08 | — | — | WO | disclosed |
| US-20090054413-A1 | Novel 5,6-Dihydropyrazolo[3,4-E] [L,4]Diazepin-4 (IH) -One Derivatives for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1931672-A1 | NOVEL 5,6-DIHYDROPYRAZOLO[3,4-E] [L,4]DIAZEPIN-4 (IH) -ONE DERIVATIVES FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE. | AstraZeneca AB (SE) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007040435-A1 | NOVEL 5,6-DIHYDROPYRAZOLO[3,4-E] [L,4]DIAZEPIN-4 (IH) -ONE DERIVATIVES FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE. | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054413-A1 | Novel 5,6-Dihydropyrazolo[3,4-E] [L,4]Diazepin-4 (IH) -One Derivatives for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease | PDE4B, PDE4A, PDE12 | HPGD 55/4885PDE7A 10/4885KCNH2 948/4885 |
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | NOX1, CYBB, NOX4 | HPGD 16/4885PDE7A 156/4885KCNH2 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.